-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

PCC Should Be Used to Reverse Xai Anticoagulants

Program: Spotlight Sessions
Session: Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Therapies, Adverse Events
Sunday, December 10, 2023, 4:30 PM-5:45 PM

Sam Schulman, MD, PhD

Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada

Disclosures: Schulman: Bayer: Honoraria; Sanofi: Honoraria; Servier: Honoraria; Daiichi-Sankyo: Honoraria; Alexion: Honoraria; Octapharma: Honoraria; Boehringer-Ingelheim: Honoraria; Hemostasis Reference Laboratory: Honoraria; International Society on Thrombosis and Haemostasis, treasurer: Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria.

OffLabel Disclosure: PCC use for Xai-associated bleeding is off label

See more of: Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?
See more of: Spotlight Sessions
Previous Presentation | Next Presentation >>